10 Participants NeededMy employer runs this trial

Uterine Transplant for Female Infertility

SG
Overseen ByStefan G Tullius, M.D.
Age: 18 - 65
Sex: Female
Trial Phase: Phase 2 & 3
Sponsor: Brigham and Women's Hospital
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 3 JurisdictionsThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

The trial aims to explore the possibility of starting a uterine transplant program to help women with Absolute Uterine Factor Infertility (AUFI) become pregnant. It involves several steps, including IVF (in vitro fertilization), uterine transplantation (also known as Uterus Transplantation or UTx), and embryo transfer, to help women achieve a full-term pregnancy. Women with AUFI who have stable home environments, supportive partners, and can produce at least six healthy embryos are ideal candidates for this trial.

As a Phase 2, Phase 3 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group and is in the final step before FDA approval. Participants have the opportunity to contribute to groundbreaking advancements in fertility treatment.

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. However, you must be able to comply with required treatments, which might include taking new medications.

What prior data suggests that uterine transplantation is safe for women with AUFI?

Research has shown that uterine transplants can be safe and effective for women unable to have children due to Absolute Uterine Factor Infertility (AUFI). Studies have found that about 19% of women who receive a transplant experience complications, such as early birth or breathing difficulties. Despite these risks, uterine transplants often result in successful pregnancies and births when the transplanted uterus functions well.

Recipients of a uterine transplant must take medications to prevent rejection of the new uterus. These medications, including Thymoglobulin, Prednisone, and Tacrolimus, are essential but may cause side effects. Over time, Mycophenolate Mofetil (MMF) is typically replaced with Azathioprine to reduce the risk of birth defects.

Overall, while risks exist, the procedure has been successful for many women. Potential participants should discuss these risks and benefits with their healthcare providers.12345

Why are researchers excited about this trial's treatment for AUFI?

Unlike traditional treatments for absolute uterine infertility, such as surrogacy or adoption, uterine transplant offers the possibility for women to carry and deliver their own child. This treatment is unique because it involves transplanting a healthy uterus from a donor, enabling natural conception through in vitro fertilization. Researchers are excited about this approach because it provides an opportunity for women with AUFI to experience pregnancy and childbirth firsthand, which is not possible with existing options. Additionally, the use of pre-screened embryos and careful management of anti-rejection medications aim to minimize risks and improve the chances of successful, full-term pregnancies.

What evidence suggests that uterine transplant might be an effective treatment for AUFI?

Research has shown that uterine transplant offers a promising option for women unable to have children due to Absolute Uterine Factor Infertility (AUFI). In this trial, women with AUFI will undergo uterine transplantation, followed by in vitro fertilization to achieve pregnancy. Studies have found that this procedure can be performed successfully and often results in high rates of live births when the transplanted uterus functions well. Recent reviews highlight improvements in the survival of the transplanted uterus, the frequency of pregnancies, and the health of newborns, indicating significant progress in the procedure. Uterine transplantation currently remains the only method for women with AUFI to become pregnant and give birth. However, some complications have been reported, so participants must carefully consider both the potential benefits and risks.13567

Who Is on the Research Team?

SG

Stefan G Tullius, M.D.

Principal Investigator

Brigham and Womens Hospital

Are You a Good Fit for This Trial?

Inclusion Criteria

Recipient: Clinical evidence of AUFI (Absolute Uterine Factor Infertility)
Recipient: Age 18-40
Recipient: Able to produce at least 6 normal embryos by IVF for future use
See 12 more

Exclusion Criteria

Recipient: Inability to comply with required treatment (taking pills, having biopsies, frequent appointments)
Donor: History of abnormal PAP smear or genital warts
Recipient: Active smoking, alcohol use or use of illicit drugs
See 15 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks
1 visit (in-person)

In Vitro Fertilization

In Vitro Fertilization is started with the goal of obtaining 6 normal embryos for implantation

8-12 weeks
Multiple visits (in-person)

Uterine Transplantation

The uterus of a suitable live donor is transplanted into the recipient

1 week
1 visit (in-person)

Embryo Transfer and Pregnancy

Up to 6 embryo transfer cycles are attempted, followed by monitoring during pregnancy

1 year for embryo transfer, 9 months for pregnancy
Regular visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment, including monitoring for complications and quality of life assessments

5 years
Regular visits (in-person)

What Are the Treatments Tested in This Trial?

Interventions

  • Uterine Transplant

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Women with AUFIExperimental Treatment1 Intervention

Uterine Transplant is already approved in United States, European Union for the following indications:

🇺🇸
Approved in United States as Uterus Transplantation for:
🇪🇺
Approved in European Union as Uterus Transplantation for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

Brigham and Women's Hospital

Lead Sponsor

Trials
1,694
Recruited
14,790,000+

Citations

Uterus Transplant in Women With Absolute Uterine-Factor ...

Uterus transplant was technically feasible and was associated with a high live birth rate following successful graft survival.

Uterine Transplantation for Absolute Uterine Factor Infertility

Recent reviews highlight progressive improvements in graft survival, pregnancy rates, and neonatal outcomes, as well as significant advancements ...

Uterine Transplant for Women With Absolute Uterine Factor ...

This is a prospective study to treat Absolute Uterine Factor Infertility (AUFI) through uterine transplantation utilizing a uterus from a living or deceased ...

Uterine Transplantation for Absolute Uterine Factor Infertility

Uterine transplantation is currently the only treatment that allows women with absolute uterine factor infertility (AUFI) to gestate and give birth.

Uterus Transplantation for Absolute Uterine Factor Infertility

Factor Infertility: A Traditional Review of Safety and Efficacy Outcomes in the First 65 Recipients of. Uterus Transplantation. Cureus. Jan 18 2021; 13(1): ...

The reproductive potential of uterus transplantation - PMC - NIH

Absolute uterine factor infertility (AUFI) is a form of infertility whereby conception and/or maintenance of pregnancy is impossible as a result of uterine ...

Uterine Transplantation for Absolute Uterine Factor Infertility

Uterus transplantation (UTx) has emerged as a promising reproductive option for women with absolute uterine factor infertility, ...